Raymond James Financial
TGTX icon

Raymond James Financial’s TG Therapeutics TGTX Stock Holding History

Raymond James Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
620,280
+193,901
+45% +$7.94M 0.01% 1177
2026
Q1 		$14.2M Sell
426,379
-203,566
-32% -$6.07M ﹤0.01% 1736
2025
Q4 		$18.8M Sell
629,945
-44,182
-7% -$1.44M 0.01% 1492
2025
Q3 		$24.4M Sell
674,127
-4,631
-0.7% -$153K 0.01% 1281
2025
Q2 		$24.4M Sell
678,758
-8,342
-1% -$311K 0.01% 1211
2025
Q1 		$27.1M Buy
687,100
+205,111
+43% +$6.9M 0.01% 1085
2024
Q4 		$14.5M Buy
+481,989
New +$13.8M 0.01% 1545

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Raymond James Financial's TGTX Position: Q2 2026 in Review

Raymond James Financial increased its TG Therapeutics (TGTX) stake by 45% in Q2 2026, buying an estimated $7.94M and bringing the position to 620,280 shares worth $34.1M. The position accounts for 0.01% of the portfolio, ranked #1177.

Raymond James Financial first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Raymond James Financial held 620,280 shares of TG Therapeutics worth $34.1M as of Q2 2026.
  • Raymond James Financial bought 193,901 TG Therapeutics shares in Q2 2026, an estimated $7.94M.
  • TG Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1177 holding.
  • Raymond James Financial first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.